CN110831627A - 用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品 - Google Patents

用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品 Download PDF

Info

Publication number
CN110831627A
CN110831627A CN201880025896.5A CN201880025896A CN110831627A CN 110831627 A CN110831627 A CN 110831627A CN 201880025896 A CN201880025896 A CN 201880025896A CN 110831627 A CN110831627 A CN 110831627A
Authority
CN
China
Prior art keywords
immunoglobulin product
immunoglobulin
administered
product
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880025896.5A
Other languages
English (en)
Chinese (zh)
Inventor
O·米尔克
J-P·拉沃
B·杜恩
M·托尔托里奇
O·岑克尔
I·范斯海克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62063037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110831627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CSL Behring AG filed Critical CSL Behring AG
Priority claimed from PCT/EP2018/060158 external-priority patent/WO2018193078A1/en
Publication of CN110831627A publication Critical patent/CN110831627A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880025896.5A 2017-04-21 2018-04-20 用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品 Pending CN110831627A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762488219P 2017-04-21 2017-04-21
US62/488,219 2017-04-21
EP17177134 2017-06-21
EP17177134.8 2017-06-21
US201762571812P 2017-10-13 2017-10-13
US62/571,812 2017-10-13
PCT/EP2018/060158 WO2018193078A1 (en) 2017-04-21 2018-04-20 Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy

Publications (1)

Publication Number Publication Date
CN110831627A true CN110831627A (zh) 2020-02-21

Family

ID=62063037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880025896.5A Pending CN110831627A (zh) 2017-04-21 2018-04-20 用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品

Country Status (6)

Country Link
US (1) US20200055922A1 (https=)
EP (1) EP3612221A1 (https=)
JP (2) JP7275044B2 (https=)
CN (1) CN110831627A (https=)
AU (2) AU2018253931A1 (https=)
CA (1) CA3060169A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074885A1 (en) * 2008-03-17 2010-03-25 Richard Schiff Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
US20110066111A1 (en) * 2009-09-17 2011-03-17 Wolfgang Teschner Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
CN103080129A (zh) * 2010-04-08 2013-05-01 巴塞尔大学医院 用于治疗和预防免疫重建炎症综合征（iris）的血浆衍生的免疫球蛋白
CN103118705A (zh) * 2010-07-19 2013-05-22 分馏及生物技术法国实验室 浓缩人免疫球蛋白组合物
CN104958761A (zh) * 2010-05-26 2015-10-07 巴克斯特国际公司 从血浆制备富含IgG的组合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019224304A1 (en) * 2018-05-23 2019-11-28 Csl Behring Ag Treatment of cidp

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074885A1 (en) * 2008-03-17 2010-03-25 Richard Schiff Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
US20110066111A1 (en) * 2009-09-17 2011-03-17 Wolfgang Teschner Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
CN103080129A (zh) * 2010-04-08 2013-05-01 巴塞尔大学医院 用于治疗和预防免疫重建炎症综合征（iris）的血浆衍生的免疫球蛋白
CN104958761A (zh) * 2010-05-26 2015-10-07 巴克斯特国际公司 从血浆制备富含IgG的组合物的方法
CN103118705A (zh) * 2010-07-19 2013-05-22 分馏及生物技术法国实验室 浓缩人免疫球蛋白组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CSL BEHRING: "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)（NCT01545076）" *
L. H. MARKVARDSEN: "Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study" *
马培奇;: "美FDA批准延长皮下注射用人免疫球蛋白制剂Hizentra的保质期至24个月" *
马培奇;: "美FDA批准第一种免疫球蛋白皮下输注剂Hizentra用作原发性免疫缺陷患者替代治疗" *

Also Published As

Publication number Publication date
JP7275044B2 (ja) 2023-05-17
JP7621411B2 (ja) 2025-01-24
US20200055922A1 (en) 2020-02-20
EP3612221A1 (en) 2020-02-26
AU2025202358A1 (en) 2025-04-24
CA3060169A1 (en) 2018-10-25
JP2020517636A (ja) 2020-06-18
AU2018253931A1 (en) 2019-11-21
JP2023099143A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
JP2013166765A5 (https=)
TW201521757A (zh) 先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
RU2014117510A (ru) Лечение ревматоидного артрита
JP2025514978A (ja) 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用
KR20230095998A (ko) 척수 근위축증을 치료하기 위한 항-프로/잠재성 마이오스타틴 항체의 용도
CN121152807A (zh) 使用抗cd40l抗体治疗多发性硬化症
CA3202575A1 (en) Treatment of raynaud's disease
JP2885517B2 (ja) 運動失調を処置するための医薬組成物
US20250326822A1 (en) Treatment of cidp
JP7621411B2 (ja) 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
WO2018193078A1 (en) Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
Opala et al. Chronic inflammatory demyelinating polyneuropathy: time to maximal recovery in patients receiving intravenous immunoglobulin therapy
Karam New Horizons in the Treatment and Management of Chronic Inflammatory Demyelinating Polyneuropathy: Expert Perspectives on Immunoglobulin Therapy
KR20260005781A (ko) 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법
Sundar Singh et al. Impact of IVIG in the Management of Guillain-Barre Syndrome: A Case Series from South India.
US20240228644A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies
WO2025093717A1 (en) Methods of improving anti-fcrn therapies
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
Young et al. 106. Gadolinium enhancement of the lumbar roots in a case of amyotrophic lateral sclerosis
JP2019531329A (ja) 女性の性機能障害を治療する医薬組成物および方法
JPH01238540A (ja) ヒトｔ細胞リンホトロピックウイルスｉ型関与脊髄症治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination